5-bromo-N-(4,4,5,5-tetradeuterio-1H-imidazol-2-yl)quinoxalin-6-amine

Request For Quotation
5-bromo-N-(4,4,5,5-tetradeuterio-1H-imidazol-2-yl)quinoxalin-6-amine Suppliers list
Company Name: Shanghai Hongye Biotechnology Co. Ltd  
Tel: 400-9205774 400-920-5774
Email: sales@glpbio.cn
Company Name: Guangzhou Dreampharm Biotechnology Co., Ltd.  
Tel: 020-36607679; 13502246435
Email: 3008233746@qq.com
Company Name: Jinan blalong chemical co. LTD  
Tel: 2710913286@qq.com
Email: 1513643261@qq.com
Company Name: ChemeGen(Shanghai) Biotechnology Co.,Ltd.  
Tel: 18818260767
Email: sales@chemegen.com
Company Name: CHINA ISOTOPE CO., LIMITED  
Tel: 02151600108 13062666369
Email: info@isotopechem.com
5-bromo-N-(4,4,5,5-tetradeuterio-1H-imidazol-2-yl)quinoxalin-6-amine Basic information
Product Name:5-bromo-N-(4,4,5,5-tetradeuterio-1H-imidazol-2-yl)quinoxalin-6-amine
Synonyms:5-bromo-N-(4,4,5,5-tetradeuterio-1H-imidazol-2-yl)quinoxalin-6-amine;5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl-4,4,5,5-d4)quinoxalin-6-amine
CAS:1184971-51-4
MF:C11H10BrN5
MW:292.14
EINECS:
Product Categories:
Mol File:1184971-51-4.mol
5-bromo-N-(4,4,5,5-tetradeuterio-1H-imidazol-2-yl)quinoxalin-6-amine Structure
5-bromo-N-(4,4,5,5-tetradeuterio-1H-imidazol-2-yl)quinoxalin-6-amine Chemical Properties
storage temp. Store at -20°C
solubility DMSO: soluble; Water: 1.5 mg/ml
form A solid
Safety Information
MSDS Information
5-bromo-N-(4,4,5,5-tetradeuterio-1H-imidazol-2-yl)quinoxalin-6-amine Usage And Synthesis
DescriptionBrimonidine-d4 is intended for use as an internal standard for the quantification of brimonidine by GC- or LC-MS. Brimonidine is an agonist of α2-adrenergic receptors (α2-ARs; Kis = 2.7, 52, and 44 nM for α2A, α2B, and α2C-ARs, respectively, in CHO cells).1 It is selective for α2-ARs over α1-ARs (Ki = 1,800 nM in human brain). Brimonidine lowers intraocular pressure in DBA/2J mice, a model of glaucoma, to control levels when applied topically to the eye as a 0.1% solution.2 It also inhibits glutamate release, prevents upregulation of NMDA receptors containing NR1 and NR2A subunits, and protects rat retinal ganglion cells against glutamate excitotoxicity in a rat model of retinal ischemia when administered at a dose of 1 mg/kg per day.3 Formulations containing brimonidine have been used in the treatment of open-angle glaucoma and ocular hypertension.
UsesBrimonidine-d4 is the deuterium labeled Brimonidine. Brimonidine (UK 14304) is a full α2-adrenergic receptor (α2-AR) agonist.
References1. Munk, S.A., Harcourt, D.A., Arasasingham, P.N., et al. Synthesis and evaluation of 2-(arylamino)imidazoles as α2-adrenergic agonists J. Med. Chem. 40(1),18-23(1997).
2. Sawada, K., Hiraoka, M., and Ohguro, H. Effect of antiglaucoma medicine on intraocular pressure in DBA/2J mice Ophthalmic Res. 55(4),205-211(2016).
3. Lee, D., Kim, K.Y., Noh, Y.H., et al. Brimonidine blocks glutamate excitotoxicity-induced oxidative stress and preserves mitochondrial transcription factor A in ischemic retinal injury PLoS One 7(10),e47098(2012).
5-bromo-N-(4,4,5,5-tetradeuterio-1H-imidazol-2-yl)quinoxalin-6-amine Preparation Products And Raw materials
Tag:5-bromo-N-(4,4,5,5-tetradeuterio-1H-imidazol-2-yl)quinoxalin-6-amine(1184971-51-4) Related Product Information
Brimonidine Brimonidine Tartrate Brimonidine Dimer 5-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine N-(4,5-Dihydro-1H-iMidazol-2-yl)-6-quinoxalinaMine BriMonidine-2,3-dione Brimonidine Impurity E Brimonidine Related Impurity 3 Hydroxy Brimonidine Brimonidine Tartrate Impurity 4 4,5-Didehydro BriMonidine